How to inject Ofatumumab

Before a patient starts taking Ofatumumab, the doctor will advise that the patient will have a blood test to make sure there is nothing that would prevent the patient from using ofatumumab safely. Ofatumumab is available in two dosage forms: a sterile, clear to opalescent, colorless, preservative-free liquid concentrate (20 mg/mL) for dilution and intravenous administration (Arzerra) and a preservative-free, clear to slightly opalescent, colorless to slightly tan subcutaneous injection for subcutaneous administration (Kesimpta).

Ofatumumab (Arzerra) is given as an intravenous infusion. Your healthcare provider will give you this medicine. You may also be given other medicines to help prevent infusion reactions. These medicines may need to be started 2 hours before you start your ofatumumab infusion. Ofatumumab must be injected slowly, and one injection may take several hours to complete. A treatment cycle is usually 28 days. Patients may only need to use the drug for the first 1 or 2 weeks of each cycle. The dosing regimen may change as the dose increases, and the doctor will decide how long to receive ofatumumab.

Ofatumumab (Kesimpta) is injected subcutaneously, usually once a month, with the first 3 doses once a week. Healthcare providers may teach patients how to use the drug correctly by themselves, and prepare the injection only when they are ready. Do not use if the medicine looks cloudy, discolored, or has particles. Avoid injecting ofatumumab into scars, moles, or stretch marks, or into skin that is red, bruised, scaly, hard, or tender. Store ofatumumab prefilled syringes in the original carton in the refrigerator. Avoid light and freezing. Do not shake the syringe.